Contact Us Today!

617-523-7900

or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?





If you would like a response, please include your contact information.

<< Return to Search Results

Shizuo Mukai, M.D.

Specialty: Retina
Phone Number: 617-573-3730
Fax: 617-573-3698
Location: Mass. Eye and Ear
243 Charles Street
Boston, MA 02114
Office Hours: Monday through Friday, 9:00 a.m. - 5:00 p.m.
Board Certification: Ophthalmology
Medical School Brown Medical School
Residency Ophthalmology, Harvard Medical School
Fellowship Vitreoretinal Surgery, Mass. Eye and Ear
Teaching Affiliation Associate Professor in Ophthalmology, Harvard Medical School
Biographical Profile:

Clinical Interests

Medical and surgical management of vitreoretinal diseases, pediatric retina, retinal tumors, genetics of retinal diseases

Research Interests

Retinal stem cells, molecular genetics of retinal diseases, new treatment approaches to retinoblastoma, retinal photography

Publications

For a full publication list, please see his CV. A representative list is available through www.pubmed.gov.

Daniels AB, Jakobiec FA, Westerfeld CB, Hagiwara A, Michaud N, Mukai S. Idiopathic subfoveal choroidal neovascular membrane in a 21-month-old child: ultrastructural features and implication for membranogenesis. J AAPOS. 2010 Jun; 14(3): 244-50.

Vavvas D, Kim I, Lane AM, Chaglassian A, Mukai S, Gragoudas E. Posterior uveal melanoma in young patients treated with proton beam therapy. Retina. 2010 Sep; 30(8): 1267-71.

Lei H, Rhéaume MA, Velez G, Mukai S, Kazlauskas A. Expression of PDGFRα is a determinant of the PVR potential of ARPE19 cells. Invest Ophthalmol Vis Sci. 2011 Aug; 52(9): 5016-21.

Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM, MacPherson D. miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev. 2011 Aug 15; 25(16): 1734-45.

Pennock S, Rheaume MA, Mukai S, Kazlauskas A. A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy. Am J Pathol. 2011 Dec; 179(6): 2931-40.